Drugs · acquisition-cost intelligence
Erythromycin
· ingredient erythromycinAntibiotics· ERYTHROMYCIN 250 mg/1; ERYTHROMYCIN 500 mg/1
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per EA
$2.87
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per EA — the trend nobody else shows. 6 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other erythromycin products, cheapest acquisition cost first. Per EA — confirm strength/form equivalence before switching.
| Product | NADAC / EA | vs this |
|---|---|---|
| erythromycin | $0.34583 | −$2.53 |
| Erythromycin | $0.66199 | −$2.21 |
| Ery | $1.24 | −$1.63 |
| E.E.S | $1.59 | −$1.28 |
| erythromycin | $2.86 | −$0.00690 |
| Erythromycin | $2.97 | +$0.10280 |
| ERY-TAB | $2.97 | +$0.10280 |
| erythromycin | $5.96 | +$3.09 |
Medicare Part D coverage · CY2026
On 303 plan formularies · typical tier 4
Prior auth 0% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.